Genmab — Marts 2019

[Tandfeen-2]

Endelig med nice

[peter12]

I 4. linie regnede de med ca 700 pts https://pharmaphorum.com/news/nice-backs-interim-funding-janssen-cancer-drug/

[E_L]

we are not there yet @Tandfeen-2 , still not 1st line and still via CDF, so far from ideal. But it is another step that will increase sales.

[E_L]

"NICE however said that the overall-survival data was ‘immature’ because more than half of the patients treated with the daratumumab combination were alive after nearly four years of follow up." this sounds like, if patients would have died quicker, it would have been easier to approve… crazy...

[peter12]

Interesting discussion between Janssen and Nice last year
. Dara could reset MM treatment https://www.nice.org.uk/guidance/ta510/documents/committee-papers-2

[Sukkeralf]

E L I guess that comment is because NICE mainly base their reimbursement on OS data

[E_L]

yes, i guess you are correct, that is what they base their cost effectiveness study on, but it feels weird to say that it is difficult to measure because they live too long... Anyway, another small step..
.

[Bulder]

What does this mean? They recommend the treatment, but will not reimburse it?

[E_L]

NHS will not directly fund it, it will be reimbursed out of the Cancer Drugs Fund (CDF), just like currently is the case with mono

[peter12]

Genmab var shortet 4,04% 28 feb. Det har ligget på 3-4% det sidste år. Det er positioner over 0,2%

[Joakim_Von_And]

Ja,, kunne der komme et bud , så de hurtigt ville i 0 ,, det ville glæde mig at de brændte nallerne lidt...

[StockBull]

2.5 - 5% det sıdste aars tıd

[StockBull]

1.5 aars tıd

[Sukkeralf]

Så kender man Genmab igen - svag som i svag.

[Tandfeen-2]

Desværre også på en grøn dag

[Helge_LarsenPI-redaktør]

Genmab og Novo følges ad med minus 0,22 og 0,26% i dag. Værre er det ikke.

[concillado]

GEN's kurs klargør blot at lægge sig favorabelt til os trofaste investorer, så vi kan full value, når vi skal brænde vores overskydende skat af lige om lidt!

[E_L]

New trial : Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) https://clinicaltrials.gov/ct2/show/NCT03871829

[E_L]

and it looks like they will give this one another try https://clinicaltrials.gov/ct2/history/NCT03346135?A=5&B=6&C=merged

[E_L]

and the Tisotumab Vedotin safety study published the results
https://clinicaltrials.gov/ct2/history/NCT02552121?A=10&B=11&C=merged